Pages that link to "Q41008859"
Jump to navigation
Jump to search
The following pages link to Juan A. Pineda (Q41008859):
Displaying 50 items.
- Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study (Q28552246) (← links)
- Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients (Q28740552) (← links)
- Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients (Q28764754) (← links)
- HCV epidemiology in high-risk groups and the risk of reinfection. (Q30245241) (← links)
- Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort (Q31114657) (← links)
- Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients (Q31115968) (← links)
- Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy (Q33422417) (← links)
- Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. (Q33423922) (← links)
- KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy (Q33430704) (← links)
- HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients. (Q33778756) (← links)
- Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients (Q34473823) (← links)
- Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. (Q34852032) (← links)
- Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment (Q35036061) (← links)
- IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians (Q35153222) (← links)
- Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses (Q35689037) (← links)
- Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes (Q35760270) (← links)
- Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection (Q35862004) (← links)
- Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. (Q35862847) (← links)
- Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort (Q35915593) (← links)
- Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. (Q36054272) (← links)
- No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014 (Q36135182) (← links)
- The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients. (Q36223683) (← links)
- Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C (Q36553967) (← links)
- Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. (Q36718901) (← links)
- Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. (Q37450742) (← links)
- The changing face of HIV/AIDS in treated patients (Q37550657) (← links)
- Host genetics. (Q37932339) (← links)
- Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). (Q38225483) (← links)
- Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. (Q38236179) (← links)
- HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. (Q38733664) (← links)
- Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: A prospective longitudinal study. (Q38942836) (← links)
- Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients (Q39877513) (← links)
- Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. (Q40043067) (← links)
- Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients (Q40092302) (← links)
- Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. (Q40190578) (← links)
- Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study (Q40328514) (← links)
- Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection (Q40352938) (← links)
- Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. (Q40360505) (← links)
- Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients (Q40399465) (← links)
- High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. (Q40437474) (← links)
- Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis (Q40439142) (← links)
- Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. (Q40463331) (← links)
- HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients. (Q40486607) (← links)
- Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users. (Q40493714) (← links)
- Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. (Q40501415) (← links)
- Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults (Q40599220) (← links)
- HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy. (Q40653324) (← links)
- Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes (Q40937004) (← links)
- IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. (Q40998744) (← links)
- Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals (Q41008656) (← links)